Chairpersons: Christopher Paul Cannon (Boston, United States of America), Dominick Joseph Angiolillo (Jacksonville, United States of America) Subtitle: Sponsored by Boehringer Ingelheim Learning Objectives: To review how the presentation of the RE-LY results 10 years ago heralded a decade of innovation in the non-Vitamin K antagonist oral anticoagulant (NOAC) treatment landscape – To assess the […]
Based on the patient characteristics of an elderly AF patient with renal impairment Dr. John W. Eikelboom will review existing data from multiple sources including RE-LY subgroup data to support the dabigatran treatment decision for this patient
Based on the patient characteristics of an AF patient with cardiovascular comorbidities Dr. John W. Eikelboom will review existing data from multiple sources including RE-LY subgroup data, GLORIA AF and RE-DUAL PCI to support the dabigatran treatment decision for this patient
Dabigatran, a direct Thrombin Inhibitor, Reduces the risk of an Intracerebral Haemorrhage: Protection of the blood brain Barrier
This is a video showing the MOA of thrombin inhibition on intracranial haemorrhage. It shows how dabigatran, a thrombin inhibitor minimises thrombin mediated damage and preserves the brain barrier, thereby minimising intracranial hemorage. It showcases the RE-LY trial as well as the confirmation of the trial by RWE.
Congress Presentation presented at AHA 2017 given by Dr. Chris Cannon with slides on a neutral background ( only Study branding) Including Q&A with Dr. Cannon and Dr. Hohnloser on FAQs related to the study results as well as the clinical implications of the results. Q&A 1: What may be the implication of the RE-DUAL […]
At ACC 2017 the RE-CIRCUIT study was presented in the Late-Breaking Clinical Trials session. Here we have a series of Q&A videos presented by Dr. Hugh Calkins Q&A 1: How do the absolute major bleeding event rates seen in RE-CIRCUIT for dabigatran etexilate and warfarin relate to those usually seen in clinical practice? Q&A 2: […]
Communicate RE-LY data including subgroups data and leverage expert opinion from Dr. John W. Eikelboom to cover: Overview of safety/efficacy profile established in RE-LY
The results from the full cohort analysis of the REVERSE-AD study provide compelling evidence for idarucizumab’s ability to immediately, completely and sustainably reverse the anticoagulant effect of dabigatran. This video summarizes the key results of the RE-VERSE AD study and shows the importance of specific reversibility in the context of anticoagulation
Dr. Dominick Angiolillo summarizes the results of the RE-DUAL PCI study showing the safety of dabigatran dual therapy post-PCI with doses approved for stroke prevention in AF. He also shows data on subgroup analysis in patients with ACS / no ACS as an index event and subgroup analysis looking at results dependent on the P2Y12 […]
In the video Dr. Gupta summarized the results of the RE-CIRCUIT study confirming the safety profile of dabigatran also in the setting of catheter ablation in AF patients. He explains that based on the RE-CIRCUIT results, interruption of dabigatran prior to ablation is no longer warranted, as reflected in current expert guidance for performing AF […]
Summary of GLORIA-AF Final Phase II: Two-year safety and effectiveness of dabigatran in patients with atrial fibrillation (summarized by Prof Gregory Lip). An educational video summarizing data presented at EHRA, Barcelona 2018.
The series of infographic animations communicate the consistency of results, how RWE supports the favorable safety profile and the importance of RWE evidence. From Clinical Studies to RWE This infographic animation communicates the consistency of results, how RWE supports the favourable safety profile and the importance of RWE evidence. Safety proven by RWE This infographic […]